ALEXION PHARMACEUTICALS, INC.

(ALXN)
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurimmune AG

01/07/2022 | 02:00am EDT

Alexion has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). NI006 specifically targets misfolded transthyretin and is designed to directly address the pathology of ATTR-CM by enabling removal of amyloid fibril deposits in the heart, with the potential to treat patients with advanced ATTR-CM. Under the agreement, Alexion will be granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. ATTR-CM is a systemic, progressive and fatal condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis.1 It remains underdiagnosed and its prevalence is thought to be underestimated due to a lack of disease awareness and the heterogeneity of symptoms.


© S&P Capital IQ 2022
All news about ALEXION PHARMACEUTICALS, INC.
05/05Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy..
AQ
04/28Ultomiris approved in the US for adults with generalised myasthenia gravis
AQ
04/26BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry
AQ
04/11PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing
AQ
03/31SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)
AQ
03/29PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat..
AQ
03/18Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
03/17AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir..
AQ
03/01AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t..
AQ
03/01Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ALEXION PHARMACEUTICALS, INC.0.00%40 336
CSL LIMITED-6.04%93 360
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-39.22%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%21 450